| Reaction Details |
|---|
 | Report a problem with these data |
| Target | C-C chemokine receptor type 3 |
|---|
| Ligand | BDBM50106929 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEBML_39486 |
|---|
| IC50 | >1000±n/a nM |
|---|
| Citation |  Kim, D; Wang, L; Caldwell, CG; Chen, P; Finke, PE; Oates, B; MacCoss, M; Mills, SG; Malkowitz, L; Gould, SL; DeMartino, JA; Springer, MS; Hazuda, D; Miller, M; Kessler, J; Danzeisen, R; Carver, G; Carella, A; Holmes, K; Lineberger, J; Schleif, WA; Emini, EA Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. Bioorg Med Chem Lett11:3099-102 (2001) [PubMed] |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| C-C chemokine receptor type 3 |
|---|
| Name: | C-C chemokine receptor type 3 |
|---|
| Synonyms: | C-C CKR-3 | C-C chemokine receptor type 3 (CCR3) | CC-CKR-3 | CCR-3 | CCR3 | CCR3_HUMAN | CD_antigen=CD193 | CKR3 | CMKBR3 | Eosinophil eotaxin receptor |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 41053.88 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P51677 |
|---|
| Residue: | 355 |
|---|
| Sequence: | MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI
KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE
IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE
TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL
IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI
YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF
|
|
|
|---|
| BDBM50106929 |
|---|
| n/a |
|---|
| Name | BDBM50106929 |
|---|
| Synonyms: | Allyl-(1-{3-(3-chloro-phenyl)-4-[(R)-4-(1H-indol-3-ylmethyl)-2,5-dioxo-imidazolidin-1-yl]-butyl}-piperidin-4-yl)-carbamic acid benzyl ester | CHEMBL107128 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C38H42ClN5O4 |
|---|
| Mol. Mass. | 668.224 |
|---|
| SMILES | Oc1c(Cc2c[nH]c3ccccc23)[nH]c(=O)n1CC(CCN1CCC(CC1)N(CC=C)C(=O)OCc1ccccc1)c1cccc(Cl)c1 |
|---|
| Structure | 
|
|---|
Search and Browse
